ART BioScience
Genetic Therapies for Duchenne Muscular Dystrophy
Company Overview
Snapshot
Founded in July 2015 by Oren Ozeri and Alon Hazan, ART BioScience operates with 1–10 employees. The company is focused on pioneering mRNA therapeutics for rare diseases, a significant technological advancement highlighted in July 2018.
Business overview
ART BioScience is a Health Tech & Life Sciences company specializing in the development of genetic therapies for Duchenne Muscular Dystrophy. The company leverages novel messenger RNA technologies and a proprietary LNP-based formulation for effective muscle delivery via systemic administration. Its core technology, optimized from lipids licensed from Professor Dan Peer's laboratory, enables efficient transfer of mRNA to muscles. ART BioScience operates within the Drugs Discovery & Development sector, targeting the Pharmaceuticals market within Life Sciences.
Log in to access full profile ›Company Intelligence Q&A
- What is ART BioScience's primary focus?
- ART BioScience specializes in developing genetic therapies for Duchenne Muscular Dystrophy using novel messenger RNA technologies.
- When was ART BioScience founded and by whom?
- ART BioScience was founded in July 2015 by Oren Ozeri and Alon Hazan.
- What is ART BioScience's core technology?
- The company's core technology involves a proprietary LNP-based formulation that optimizes lipid delivery for efficient transfer of mRNA to muscles via systemic administration.
- What significant technological milestone has ART BioScience achieved?
- In July 2018, ART BioScience was recognized for pioneering mRNA therapeutics for the treatment of rare diseases, specifically within the Pharmaceuticals & Diagnostics category.
- What markets does ART BioScience serve?
- ART BioScience operates within the Health Tech & Life Sciences sector, with a focus on the Pharmaceuticals market for rare diseases.